Over the past few decades Cancer has emerged as a major public health concern worldwide. Cancer is the second leading cause of deaths that takes place worldwide. Every sixth death is due to cancer, and in 2018 was estimated to be responsible for 9.6 million deaths. Costing people quality of lives and eventually lea...
Find MoreBoehringer Ingelheim’s Ofev (nintedanib) has received FDA recommendation for the treatment of chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype Interstitial Lung Disease - ILD – a group of a large number of lung disorders resulting in scarring or fibrosis of lungs, caused by conditi...
Find MoreThe Non-small cell lung cancer therapeutics market is anticipated to improve owing to better diagnostics methodologies and treatment options across the world. This would expand the NSCLC market size enabling the drug manufacturers to penetrate more into the market. Companies across the globe are diligently working ...
Find MoreAn estimated number of 18.1 million new cancer cases were registered last year, according to A Cancer Journal for Clinicians 2018;0:1‐31. Moreover, it is a leading cause of global deaths. The deaths due to cancer remain recognized as the only barrier in the increasing life expectancy in the world. The incidence, as...
Find MoreThe drug Imfinzi (durvalumab) has failed to come up as an effective treatment option for treating non-small cell lung cancer (NSCLC). The result of the NEPTUNE study was not much of a promising one and has been disclosed completely. The Pharma giant, AstraZeneca, has announced the incompetence of its lead candidate...
Find MoreSNAPSHOTS: Copiktra receives FDA approval for CLL and FL, Relief for tazemetostat developers after FDA lifted partial clinical hold, Conference highlights from 19th WCLC The United States Food and Drug Administration (USFDA) has granted approval to Verastem’s Copiktra (duvelisib), for the treatment of patients with...
Find MoreBexion Pharmaceuticals’ Early-Stage Cancer Drug, BXQ-350 Hailed as Game Changer For the Treatment of solid tumors and gliomas Bexion Pharmaceuticals’ investigational cancer treatment, BXQ-350, is receiving lots of mainstream media coverage as a potential game-changer. BXQ-350 is a formulation of a syntheticall...
Find MoreThe discovery of Cyclin Dependent Kinases (CDKs) is a result of increasing number of cancer cases worldwide. The development of CDKs has changed the paradigm for cancer treatment and it has gradually become an interesting area of research in oncology. The research on CDK inhibitors gained momentum because of the fre...
Find MoreMerck beats Q1 estimates as Keytruda sales double Merck is the victim of its own success, judging from its first-quarter report. The company beat sales and earnings estimates, and it upped its guidance for the year, despite some significant suffering from generic competition. Sales of its hit immuno-oncology drug Ke...
Find MoreMerck sells biosimilars business to Fresenius Merck has divested its biosimilars business to fellow German drug maker Fresenius in a deal potentially worth 670 million euros. The drug maker said the move is aligned with a strategy of focusing on innovative medicines while enabling it to exploit its biosimilars portf...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.